

James T. Dalton, Ph.D.

**Executive Vice President and Provost,
Professor of Translational Science and Medicine, College of Community Health Sciences
Professor of Chemical and Biological Engineering, College of Engineering
University of Alabama**

Dr. James T. Dalton is an accomplished academic leader, researcher, and innovator whose career spans leadership roles in higher education, biotechnology, and pharmaceutical research. Since 2020, he has served as Executive Vice President and Provost at The University of Alabama, where he oversees the academic, research, and service missions of 13 colleges and academic divisions encompassing more than 2,000 faculty, 4,500 staff, and 40,000 students, with an annual academic budget exceeding \$1.2 billion.

At Alabama, Dr. Dalton has led major institutional initiatives to enhance student success, expand research productivity, and modernize academic programs. He established the UA Teaching Academy, restructured the College of Continuing Studies into the Office of Teaching Innovation and Digital Education, and launched programs to improve undergraduate retention and reduce class sizes. Under his leadership, the university achieved a 60% increase in sponsored research awards, implemented a new general education core curriculum, and successfully completed reaffirmation of accreditation by the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC).

Prior to joining Alabama, Dr. Dalton served as Dean of the College of Pharmacy at the University of Michigan, where he led one of the nation's top-ranked pharmacy programs and oversaw substantial growth in research funding and academic innovation. During his tenure, the college's U.S. News & World Report ranking rose from No. 7 to No. 3, research expenditures doubled, and new undergraduate and master's programs were launched. The college also exceeded its capital campaign goal, securing nearly \$25 million in new scholarships, endowments, and facility funding.

Dr. Dalton's career bridges academia and the private sector. As Chief Scientific Officer and Vice President for Preclinical Research and Development at GTx, Inc., he directed teams responsible for the discovery and clinical development of novel selective androgen receptor modulators (SARMs) and other therapeutics in oncology and endocrinology. His pioneering work in drug discovery led to more than 100 issued U.S. patents and over 500 international patents, and his research has been cited more than 21,000 times, reflecting his global influence in pharmaceutical sciences.

A Fellow of the American Association for the Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS), Dr. Dalton was elected to the National Academy of Medicine in 2019 in recognition of his contributions to biomedical research and academic leadership. His numerous honors include the Nicholas Bodor Distinguished Lectureship at the University of Florida, the Rho Chi Lecture Award, and distinguished alumni awards from both The Ohio State University and the University of Cincinnati.

Dr. Dalton earned his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry and completed a postdoctoral fellowship at The Ohio State University, following a B.S. in Pharmacy (Magna Cum Laude) from the University of Cincinnati.